Literature DB >> 9546439

Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast.

J M Flaman1, V Robert, S Lenglet, V Moreau, R Iggo, T Frebourg.   

Abstract

Recent studies have suggested that a rare class of p53 mutants found in tumours has a subtle transcriptional defect affecting bax induction but not p21 induction. We have therefore developed simple functional assays in yeast which can be used to identify these mutants. Analysis of 51 different mutations observed in human tumours showed that all mutants tested scored as mutant with the bax reporter strain but nine scored as wild-type with the p21 reporter strain. These results, which can be explained by the lower affinity of the p53 protein for the bax site, may suggest that p21 is not the key target of p53 mutations in tumours. Since p21 status has recently been shown to modulate the chemotherapeutic and radiotherapeutic sensitivities of cancerous cells, the functional assays described here may have important clinical implications.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9546439     DOI: 10.1038/sj.onc.1201889

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast.

Authors:  Jana Smardová; Sárka Pavlová; Hana Koukalová
Journal:  Pathol Oncol Res       Date:  2003-02-11       Impact factor: 3.201

2.  Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.

Authors:  Jennifer J Jordan; Alberto Inga; Kathleen Conway; Sharon Edmiston; Lisa A Carey; Lin Wu; Michael A Resnick
Journal:  Mol Cancer Res       Date:  2010-04-20       Impact factor: 5.852

Review 3.  p53 functional assays: detecting p53 mutations in both the germline and in sporadic tumours.

Authors:  R S Camplejohn; J Rutherford
Journal:  Cell Prolif       Date:  2001-02       Impact factor: 6.831

4.  The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30.

Authors:  Ophira M Ginsburg; Mohammad R Akbari; Zeba Aziz; Robert Young; Henry Lynch; Parviz Ghadirian; Andre Robidoux; Julian Londono; Gonzalo Vasquez; Magda Gomes; Mauricio Magalhaes Costa; Constantine Dimitrakakis; Gustavo Gutierrez; Robert Pilarski; Robert Royer; Steven A Narod
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

5.  BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.

Authors:  Christian Monnerat; Agnès Chompret; Caroline Kannengiesser; Marie-Françoise Avril; Nicolas Janin; Alain Spatz; Jean-Marc Guinebretière; Catalin Marian; Michel Barrois; Françoise Boitier; Gilbert M Lenoir; Brigitte Bressac-de Paillerets
Journal:  Fam Cancer       Date:  2007-07-12       Impact factor: 2.375

6.  Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein.

Authors:  Jinwoo Ahn; Masha V Poyurovsky; Nicole Baptiste; Rachel Beckerman; Christine Cain; Melissa Mattia; Kristine McKinney; Jianmin Zhou; Andrew Zupnick; Vanesa Gottifredi; Carol Prives
Journal:  Cell Cycle       Date:  2009-05-15       Impact factor: 4.534

7.  Transcriptional functionality of germ line p53 mutants influences cancer phenotype.

Authors:  Paola Monti; Yari Ciribilli; Jennifer Jordan; Paola Menichini; David M Umbach; Michael A Resnick; Lucio Luzzatto; Alberto Inga; Gilberto Fronza
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

8.  DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance.

Authors:  Alexey V Danilov; Divas Neupane; Archana Sidalaghatta Nagaraja; Elena V Feofanova; Leigh Ann Humphries; James DiRenzo; Murray Korc
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

Review 9.  p53, p63 and p73 in the wonderland of S. cerevisiae.

Authors:  Marc Blondel; Cécile Voisset; Olivier Billant
Journal:  Oncotarget       Date:  2017-06-16

10.  Investigations on a clinically and functionally unusual and novel germline p53 mutation.

Authors:  J Rutherford; C E Chu; P M Duddy; R S Charlton; P Chumas; G R Taylor; X Lu; D M Barnes; R S Camplejohn
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.